Follow the Pundits

Tag: MDGL

Editorial illustration of scientist-investors analyzing biotech data with glowing tickers MDGL, BGNE, and INCY, representing Baker Bros’ science-driven investing strategy.

Madrigal, BeiGene, and Biotech Alpha: Inside the “Gene-ius” Kingmakers of Baker Bros. 2025

Biotech Jedi at work. Baker Bros’ 2025 victory lap shows how Madrigal, BeiGene, and ruthless conviction turned science into serious alpha.

Read entire article

Tags: ACAD, Acadia Pharma, Alkermes, ALKS, Baker Bros, Baker Bros Advisors, BeiGene, best hedge funds, BGNE, Biotech Investing, Concentrated Portfolios, featured-hedge-funds, FUNanc1al Edge, FUNanc1al Humor, FUNanc1al Investing, FunFund Index, Healthcare Innovation, Hedge Funds, hub-hedge, INCY, Incyte, INSM, Insmed, Long-Term Investing, Madrigal Pharmaceuticals, Market Leaders, MDGL, Revolution Medicines, RVMD
Cartoon of hedge fund managers conducting a biotech orchestra, with Madrigal Pharmaceuticals (MDGL) rocket blasting off.

Biotech Hedge Fund Extraordinaire Baker Bros. Advisors LP Adds To Its Stake in Madrigal Pharmaceuticals (MDGL): Should You Buy?

When the Baker Bros. — biotech’s most famous hedge fund — start scooping up more shares of Madrigal Pharma (MDGL), you know something’s cooking. With Rezdiffra sales booming, losses shrinking, and Wall Street titans circling, the tune of this Madrigal might be worth humming 🎶.

Read entire article

Tags: BakerBros, Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, Biotech Investments, Biotech Stocks, BiotechGrowth, BiotechHumor, BiotechInvesting, Biotechnology, Biotechnology Innovation, BiotechStocks, Funanc1alBiotech, Growth in Biotech, GrowthStocks, HedgeFunds, Investing, MDGL, MDGL Stock, NASH, Pharmaceuticals, StocksToWatch, WallStreet